UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Iressa [epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI)] has been reported to
activity against Non-small-cell Lung Cancer (NSCLC) failed previous chemotherapy. UFUR was
found to have anti-angiogenesis effect when long term treatment was given. Combination of
EGFR-TKI and anti-angiogenesis agents is a novel treatment.